Straits Times Index
3,330.01 -8.93 (-0.27%) S&P 500
5,354.03 +62.69 (+1.18%) Dow
38,807.33 +96.04 (+0.25%) Nasdaq
17,187.90 +330.86 (+1.96%) Bitcoin USD
71,138.27 +620.38 (+0.88%) CMC Crypto 200
1,525.12 +51.38 (+3.49%)
AMGN Jul 2024 370.000 call
| Previous close | 0.3300 |
| Open | 0.3000 |
| Bid | 0.0900 |
| Ask | 1.5000 |
| Strike | 370.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.3000 - 0.3300 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.64k |
PR NewswireAMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 45th Annual Global Healthcare Conference at 9:20 a.m. ET on Monday, June 10, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general pu
BenzingaAmgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
On Wednesday, Amgen Inc (NASDAQ:AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna (inebilizumab-cdon) for Immunoglobulin G4-related disease, a systemic autoimmune fibroinflammatory multiorgan disease, usually involving the pancreas. Amgen added Uplizna via a $27.8 billion acquisition of Horizon Therapeutics and recorded sales of $80 million in the first quarter of 2024. The trial met its primary endpoint, showing a statistically significant 87%
PR NewswireAMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
Amgen (NASDAQ:AMGN) today announced positive topline results from its randomized, double-blind, multicenter, placebo-controlled Phase 3 clinical trial (NCT04540497) evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) for the treatment of Immunoglobulin G4-related disease (IgG4-RD).
